详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Biotherapy, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, P.R. China. [2]Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, P.R. China. [3]Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, P.R. China. [4]The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, PR China. [5]Department of Intensive Care Unit, West China HospitalSichuan University, Chengdu 610041, PR China. [6]Integrated Traditional and Western Medicine Department, Qingdao Central Hospital, Qingdao University, Qingdao, Shandong 266042, P.R. China. [7]Institute of Respiratory Health, Frontiers Science Center for Disease‑Related Molecular Networks, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, P.R. China.

出处：

DOI：

关键词： Trastuzumab deruxtecan (DS-8201a) Adverse events Progression free survival Human epidermal growth factor receptor 2 Breast cancer Gastric cancer

摘要：

This study aimed to explore the efficiency and safety of the new generation antibody-drug conjugate Trastuzumab deruxtecan (DS-8201a) in treating HER2-positive solid cancers.By searching PubMed, Medline and Ovid for all clinical trials related to the safety and efficacy of DS-8201a. Event rates were calculated for all adverse events (AEs) to evaluate the safety of DS-8201a. Objective response rate (ORR) and progression-free survival (PFS) were summarized to assess the potency of DS-8201a.The AEs with event rates greater than 30% regardless of grades were nausea, decreased appetite, vomiting, fatigue, anemia, decreased neutrophil count, alopecia and diarrhea. In the grade 3 or more, decreased neutrophil count, anemia and decreased white blood cell count were the only three AEs with event rates greater than 10% (20.3, 15.0 and 10.3%). The median PFS of patients with breast cancer, gastric cancer and other HER2-positive solid cancers were 9.0-22.1, 3.0-8.3 and 4.1-11.9 months. The median ORR was 37-79.9% in patients with breast and gastric cancer and 28.3-55% in patients with other HER2-positive cancers.DS-8201a plays an active role in treating HER2-positive cancers, especially breast and gastric cancer, which have HER2 amplification. The most common AEs of DS-8201a were related to gastrointestinal and hematological system. Decreased white blood cell count and appetite were the AEs occurred with high grades.© 2022. The Author(s).

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 2 区

医学

小类 | 3 区肿瘤学

第一作者：

第一作者机构： [1]Department of Biotherapy, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610041, Sichuan, P.R. China. [2]Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, P.R. China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Nuclear Morphological Characteristics in Breast Cancer: Correlation with Hormone Receptor and Human Epidermal Growth Factor Receptor 2. [2]Nuclear Morphological Characteristics in Breast Cancer: Correlation with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 [3]Efficacy and safety of tucidinostat in patients with advanced hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: real-world insights [4]Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China [5]Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial [6]A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients [7]NFIB promotes the progression of gastric cancer by upregulating circMAP7D1 to stabilize HER2 mRNA. [8]Relationship between mammographic calcifications and the clinicopathologic characteristics of breast cancer in Western China: a retrospective multi-center study of 7317 female patients [9]Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study. [10]Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer